| Date | Time | Source | Announcement |
|---|---|---|---|
| 20 Jan 2000 | 02:14 PM | Collaboration Agreement Signed - Replacement | |
| 20 Jan 2000 | 11:08 AM | Collaboration Agreement Signed with IDM | |
| 17 Jan 2000 | 07:01 AM | Issue of Shares | |
| 07 Jan 2000 | 07:01 AM | New Development in Cancer Therapy | |
| 21 Dec 1999 | 02:02 PM | Acquisition of Novel Antibody Technology Complete | |
| 22 Nov 1999 | 04:11 PM | Holding in Company | |
| 16 Nov 1999 | 07:14 AM | Preclinical Results - Parkinson's Disease Product | |
| 17 Aug 1999 | 07:30 AM | Interim Results | |
| 26 Jul 1999 | 09:17 AM | Directorate |
Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.
Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.
Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.